SELLAS Life Sciences Group, Inc. 8-K

What Happened
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K (Mar 11, 2026) reporting that the company received proceeds from exercises of common stock warrants after December 31, 2025. The filing states approximately $26.5 million had been received as of the filing date, and since January 8, 2026 an additional ~$16.1 million was received, for a total of approximately $42.6 million in proceeds subsequent to December 31, 2025. As of March 11, 2026, SELLAS reported 179,536,724 shares of common stock outstanding.

Key Details

• Approximately $26.5 million in warrant-exercise proceeds were received as of the 8-K filing date.
• An additional ~$16.1 million was received since January 8, 2026, bringing total post-12/31/2025 proceeds to about $42.6 million.
• Reported shares outstanding as of March 11, 2026: 179,536,724 common shares.
• Item reported under 8.01 (Other Events); financial statements exhibit noted under 9.01.

Why It Matters
The warrant exercises provide a meaningful infusion of cash (~$42.6M), improving the company’s liquidity position. At the same time, the increase in shares outstanding (179.54 million) represents dilution that investors should consider when assessing per-share metrics (e.g., earnings per share, ownership percentages). This 8-K is an update on capital activity, not an earnings or management-change filing.